ABSTRACT

This invention provides a compound of the formula:

5

10

15

$$R^{2}-S \xrightarrow{C_{2}} R^{3}R^{4} \xrightarrow{R^{5}} R^{1}$$

$$(R^{6})_{m} (R^{7})_{n}$$

$$(I)$$

or its pharmaceutically acceptable salt thereof, wherein A is partially unsaturated or unsaturated five membered heterocyclic, or partially unsaturated or unsaturated five membered carbocyclic, wherein the 4-(sulfonyl)phenyl and the 4-substituted phenyl in the formula (I) are attached to ring atoms of Ring A, which are adjacent to each other; R¹ is optionally substituted aryl or heteroaryl, with the proviso that when A is pyrazole, R¹ is heteroaryl; R² is C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₁₋₄ alkylarnino, C₁₋₄ dialkylamino or amino; R³, R⁴ and R⁵ are independently hydrogen, halo, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl or the like; or two of R³, R⁴ and R⁵ are taken together with atoms to which they are attached and form a 4-7 membered ring; R⁶ and R⁷ are independently hydrogen, halo, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, C₁₋₄ alkylamino or N,N-di C₁₋₄ alkylamino; and m and n are independently 1, 2, 3 or 4.

This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.